Regeneron Pharmaceuticals, Inc.のROE推移

損益計算書

	2018/12/31	2019/12/31	2020/12/31	2021/12/31	2022/12/31
Product	4,106	4,834	5,568	12,117	6,894
Sanofi collaboration revenue
Other collaboration revenue
Other revenue
Revenue from contract with customer
Research and development
Acquired in-process research and development
Selling, general, and administrative
Product
Cost of collaboration and contract manufacturing
Other operating (income) expense, net
Total expenses
Income from operations
Other income (expense), net
Interest expense
Total other income (expense)
Income before income taxes
Income tax expense
Net income
Earnings Per Share, Basic
Earnings Per Share, Diluted
Net income
Unrealized (loss) gain on debt securities
Unrealized gain (loss) on cash flow hedges
Comprehensive income